company background image
PODD

Insulet NasdaqGS:PODD Stock Report

Last Price

US$230.59

Market Cap

US$16.0b

7D

-9.6%

1Y

-16.6%

Updated

27 Sep, 2022

Data

Company Financials +
PODD fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance3/6
Financial Health2/6
Dividends0/6

PODD Stock Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.

Insulet Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Insulet
Historical stock prices
Current Share PriceUS$230.59
52 Week HighUS$324.81
52 Week LowUS$181.00
Beta0.72
1 Month Change-13.69%
3 Month Change3.90%
1 Year Change-16.62%
3 Year Change41.61%
5 Year Change313.61%
Change since IPO1,344.80%

Recent News & Updates

Sep 20

Insulet automated insulin delivery system Omnipod 5 gets CE mark

Insulet's (NASDAQ:PODD) Omnipod 5 automated insulin delivery system received CE mark in EU for individuals aged two years and older with type 1 diabetes. Omnipod 5 is the first CE marked tubeless hybrid closed loop system (also known as automated insulin delivery) which integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) system to automatically adjust insulin, the company said in a Sept. 20 press release. Insulet expects Omnipod 5 to be available in select countries starting mid-2023.

Sep 05
The Return Trends At Insulet (NASDAQ:PODD) Look Promising

The Return Trends At Insulet (NASDAQ:PODD) Look Promising

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...

Shareholder Returns

PODDUS Medical EquipmentUS Market
7D-9.6%-6.4%-5.8%
1Y-16.6%-31.4%-22.1%

Return vs Industry: PODD exceeded the US Medical Equipment industry which returned -32.3% over the past year.

Return vs Market: PODD exceeded the US Market which returned -23.7% over the past year.

Price Volatility

Is PODD's price volatile compared to industry and market?
PODD volatility
PODD Average Weekly Movement5.5%
Medical Equipment Industry Average Movement8.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: PODD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: PODD's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20002,300Jim Hollingsheadhttps://www.insulet.com

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia.

Insulet Fundamentals Summary

How do Insulet's earnings and revenue compare to its market cap?
PODD fundamental statistics
Market CapUS$16.00b
Earnings (TTM)US$34.60m
Revenue (TTM)US$1.18b

462.5x

P/E Ratio

13.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PODD income statement (TTM)
RevenueUS$1.18b
Cost of RevenueUS$376.20m
Gross ProfitUS$801.90m
Other ExpensesUS$767.30m
EarningsUS$34.60m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 03, 2022

Earnings per share (EPS)0.50
Gross Margin68.07%
Net Profit Margin2.94%
Debt/Equity Ratio334.2%

How did PODD perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PODD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PODD?

Other financial metrics that can be useful for relative valuation.

PODD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue14.2x
Enterprise Value/EBITDA107.7x
PEG Ratio9.8x

Price to Sales Ratio vs Peers

How does PODD's PS Ratio compare to its peers?

PODD PS Ratio vs Peers
The above table shows the PS ratio for PODD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average6.3x
STE STERIS
3.4x7.2%US$16.1b
HOLX Hologic
3x-1.9%US$15.9b
ABMD Abiomed
10.5x14.3%US$11.1b
IDXX IDEXX Laboratories
8.3x8.9%US$27.5b
PODD Insulet
13.6x15.8%US$16.0b

Price-To-Sales vs Peers: PODD is expensive based on its Price-To-Sales Ratio (13.6x) compared to the peer average (6.3x).


Price to Earnings Ratio vs Industry

How does PODD's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: PODD is expensive based on its Price-To-Sales Ratio (13.6x) compared to the US Medical Equipment industry average (3.8x)


Price to Sales Ratio vs Fair Ratio

What is PODD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PODD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio13.6x
Fair PS Ratio8.4x

Price-To-Sales vs Fair Ratio: PODD is expensive based on its Price-To-Sales Ratio (13.6x) compared to the estimated Fair Price-To-Sales Ratio (8.4x).


Share Price vs Fair Value

What is the Fair Price of PODD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PODD ($230.59) is trading above our estimate of fair value ($121.69)

Significantly Below Fair Value: PODD is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Insulet forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


47.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PODD's forecast earnings growth (47.1% per year) is above the savings rate (1.9%).

Earnings vs Market: PODD's earnings (47.1% per year) are forecast to grow faster than the US market (14.7% per year).

High Growth Earnings: PODD's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PODD's revenue (15.8% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: PODD's revenue (15.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PODD's Return on Equity is forecast to be high in 3 years time (24.4%)


Discover growth companies

Past Performance

How has Insulet performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


43.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PODD has high quality earnings.

Growing Profit Margin: PODD became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: PODD has become profitable over the past 5 years, growing earnings by 43.3% per year.

Accelerating Growth: PODD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: PODD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.6%).


Return on Equity

High ROE: PODD's Return on Equity (8.2%) is considered low.


Discover strong past performing companies

Financial Health

How is Insulet's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PODD's short term assets ($1.3B) exceed its short term liabilities ($279.3M).

Long Term Liabilities: PODD's short term assets ($1.3B) do not cover its long term liabilities ($1.4B).


Debt to Equity History and Analysis

Debt Level: PODD's net debt to equity ratio (166.4%) is considered high.

Reducing Debt: PODD's debt to equity ratio has reduced from 519.9% to 334.2% over the past 5 years.

Debt Coverage: PODD's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: PODD's interest payments on its debt are not well covered by EBIT (1.9x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Insulet current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Insulet Dividend Yield vs Market
How does Insulet dividend yield compare to the market?
SegmentDividend Yield
Company (Insulet)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Medical Equipment)1.9%
Analyst forecast in 3 Years (Insulet)0%

Notable Dividend: Unable to evaluate PODD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PODD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PODD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PODD's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PODD has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Jim Hollingshead (59 yo)

3.17yrs

Tenure

US$289,815

Compensation

Dr. James R. Hollingshead, also known as Jim, Ph.D. had been President of Sleep & Respiratory Care Business at ResMed Inc. since July 2020 until May 05, 2022 and served as its President of Sleep Business s...


Leadership Team

Experienced Management: PODD's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: PODD's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PODD insiders have only sold shares in the past 3 months.


Recent Insider Transactions

NasdaqGS:PODD Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
24 Aug 22SellUS$766,296Bret ChristensenIndividual2,900US$264.24
06 Jun 22SellUS$1,291,920Charles AlpucheIndividual6,000US$215.32

Ownership Breakdown

What is the ownership structure of PODD?
Owner TypeNumber of SharesOwnership Percentage
State or Government40,2380.06%
Individual Insiders314,9040.4%
Institutions72,576,81499.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 82.56% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.03%
Capital Research and Management Company
11,122,743$2.6b-2.74%0.18%
14.94%
FMR LLC
10,366,196$2.4b0.14%0.23%
9.12%
The Vanguard Group, Inc.
6,327,879$1.5b2%0.03%
7.43%
Wellington Management Group LLP
5,155,342$1.2b53.31%0.22%
6.83%
BlackRock, Inc.
4,737,373$1.1b6.18%0.03%
5%
T. Rowe Price Group, Inc.
3,467,820$799.6m-0.71%0.1%
2.4%
ClearBridge Investments, LLC
1,667,284$384.5m-1.74%0.36%
2.05%
State Street Global Advisors, Inc.
1,425,006$328.6m-2.31%0.02%
1.92%
J.P. Morgan Asset Management, Inc.
1,333,654$307.5m3.22%0.06%
1.78%
D1 Capital Partners L.P.
1,235,820$285.0m-14.3%5.91%
1.71%
PRIMECAP Management Company
1,183,600$272.9m-4.09%0.25%
1.69%
Columbia Management Investment Advisers, LLC
1,174,700$270.9m1.27%0.08%
1.31%
Geode Capital Management, LLC
911,952$210.3m1.25%0.03%
1.17%
William Blair Investment Management, LLC
809,958$186.8m5.07%0.35%
1.16%
Echo Street Capital Management, LLC
807,643$186.2m0.65%1.73%
0.9%
Fred Alger Management, LLC
621,743$143.4m-20.63%0.69%
0.89%
Invesco Ltd.
618,885$142.7m-7.1%0.05%
0.85%
Goldman Sachs Asset Management, L.P.
587,183$135.4m12.95%0.06%
0.83%
Franklin Resources, Inc.
574,924$132.6m1.47%0.06%
0.82%
Allspring Global Investments, LLC
569,385$131.3m-17.32%0.21%
0.79%
Norges Bank Investment Management
549,739$126.8m0%0.02%
0.76%
Morgan Stanley, Investment Banking and Brokerage Investments
529,606$122.1m7.19%0.02%
0.75%
Marshall Wace LLP
518,576$119.6m32.88%0.33%
0.73%
Viking Global Investors LP
503,401$116.1m-8.04%0.55%
0.72%
Rock Springs Capital Management LP
502,000$115.8m4.21%3.33%

Company Information

Insulet Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Insulet Corporation
  • Ticker: PODD
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$16.004b
  • Shares outstanding: 69.40m
  • Website: https://www.insulet.com

Number of Employees


Location

  • Insulet Corporation
  • 100 Nagog Park
  • Acton
  • Massachusetts
  • 1720
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PODDNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2007
GOVDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2007
PODD *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMay 2007
P2OD34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 30 REPR 1 COMBRBRLJan 2022

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/27 00:00
End of Day Share Price2022/09/27 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.